ArticleFrontiers in genetics2025
Impact of nonsynonymous single nucleotide polymorphisms in
Article in Frontiers in genetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Thrombosis is a serious vascular disorder influenced by genetic factors, including nonsynonymous single nucleotide polymorphisms (nsSNPs) in the Methods: We employed a multi-layered computational approach to analyze 217 nsSNPs in the Results: Our integrated analysis identified three high-risk nsSNPs-T174I, N136I, and L168P-that detrimentally affect EPCR function. These variants disrupt critical glycosylation sites, α-helix integrity, and catalytic residues, leading to increased root mean square deviation (RMSD) and root mean square fluctuation (RMSF), reduced hydrogen bonding, and higher solvent-accessible surface area (SASA) in mutants compared to the wild-type. Disease association tools further linked these mutations to an elevated thrombotic risk. Discussion: These findings suggest that the identified nsSNPs destabilize EPCR by altering its structural dynamics and reducing its capacity to activate protein C. This provides mechanistic insight into how Conclusion: Our study demonstrates that deleterious nsSNPs in the
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.